RxDoctor Payments Data

Jonathan Flescher, MD

Internal Medicine · Raleigh, NCNPI 1558356618

Payments from drug & device makers

$675in general payments, 2019–2025

Across 43 payments — averaging $15.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$176
  • Johnson & Johnson$135
  • Amgen$80
  • Pfizer$63
  • Daiichi Sankyo Inc.$36
  • E.r. Squibb & Sons, L.L.C.$35
  • plus $150 from 8 others

What the payments were for

  • Food & beverage$675100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$675 in reported general payments places this provider in the 65th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$120,060
Medicare patients
282
Services billed
4,267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$119,971
Trelegy ElliptaFluticasone/Umeclidin/Vilanter62$74,410
OzempicSemaglutide37$50,497
JardianceEmpagliflozin33$40,994
Breo ElliptaFluticasone/Vilanterol50$26,562
MyrbetriqMirabegron30$26,140
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr41$23,862
XareltoRivaroxaban32$22,125
TrulicityDulaglutide15$21,823
Arnuity ElliptaFluticasone Furoate53$12,767
FarxigaDapagliflozin Propanediol14$12,147
Spiriva RespimatTiotropium Bromide22$11,022
Repatha SureclickEvolocumab12$9,631
Advair HfaFluticasone Propion/Salmeterol21$7,075
DuleraMometasone/Formoterol15$6,610

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$63$119,97197 claims
Boehringer IngelheimJardiance, Spiriva Respimat$34$52,01655 claims
Novo NordiskOzempic$22$50,49737 claims
Johnson & JohnsonXarelto$135$22,12532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →